- About Circio
- CEO Statement
- Pipeline
- Management Team
- Board of Directors
- Careers
- The Norwegian Transparency Act

- Circio AB
- circVec platform

Clinical programs

- KRAS program
- Publications

- Press releases
- Events
- Reports
- Presentations
- Prospectus
- Debt
- Share information
- Contact

- Press releases
- Events
- Subscribe
- Contact

About
circRNA
- Circio AB
- circVec platform
Clinical programs
- KRAS program
- Publications
Partnering
- Partnering
Investors
Media
Contacts
- Offices
- Investors & Media

Search for:

Targovax ASA: ONCOS-102 Mechanism of Action -video released on the website

January 26, 2015

Press release - Non-regulatory

Watch the video: ONCOS-102 Mechanism of Action

IR contact

Dr Erik Digman Wiklund

CEO

erik.wiklund@targovax.com

+47 41 33 35 36

Dr Lubor Gaal

Chief Financial Officer

lubor.gaal@circio.com

(+34) 683 343 811

Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines.

About
circRNA
Clinical programs
Partnering
Investors
Media
Contacts

CONTACT

Circio Holding ASA
Email: contact@circio.com

Cookies
Privacy policy

STAY CONNECTED